Y Intercept Hong Kong Ltd Increases Holdings in Natera, Inc. (NASDAQ:NTRA)

Y Intercept Hong Kong Ltd grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 211.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,144 shares of the medical research company’s stock after acquiring an additional 21,160 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Natera were worth $4,930,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Blue Trust Inc. increased its stake in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc increased its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares during the period. Covestor Ltd increased its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the period. Principal Securities Inc. increased its stake in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares during the period. Finally, True Wealth Design LLC purchased a new position in shares of Natera in the third quarter valued at about $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

NASDAQ:NTRA opened at $162.31 on Monday. Natera, Inc. has a 12 month low of $69.74 and a 12 month high of $183.00. The company has a market capitalization of $21.43 billion, a P/E ratio of -92.22 and a beta of 1.66. The business’s 50-day moving average is $167.98 and its 200 day moving average is $145.85. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 4,858 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $166.59, for a total transaction of $809,294.22. Following the sale, the insider now owns 114,912 shares of the company’s stock, valued at approximately $19,143,190.08. The trade was a 4.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 295,772 shares of company stock worth $49,741,699 over the last quarter. Company insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group boosted their target price on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Morgan Stanley boosted their price objective on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. The Goldman Sachs Group boosted their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Piper Sandler boosted their price target on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Finally, Robert W. Baird boosted their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.